1. US team concludes shorter recovery with remdesivir  NHK WORLD
  2. Remdesivir speeds recovery in cases of severe COVID-19  UW Medicine Newsroom
  3. View Full coverage on Google News
A research group led by the US National Institute of Heath has concluded the drug remdesivir helps shorten recovery time for COVID-19 patients.A research group led by the US National Institute of Heath has concluded the drug remdesivir helps shorten recovery time for COVID-19 patients.

US team concludes shorter recovery with remdesivir | NHK WORLD-JAPAN News

Anti-viral drug remdesivir cuts recovery times in coronavirus patients, according to the full results of a trial published Friday night.Anti-viral drug remdesivir cuts recovery times in coronavirus patients, according to the full results of a trial published Friday night.

Anti-viral drug effective against coronavirus, study finds

The drug helped patients infected with the novel coronavirus heal faster, allowing them to return home after about 11 days, compared to 15 days for those who were treated with a placebo, according to the report in the New England Journal of Medicine.The drug helped patients infected with the novel coronavirus heal faster, allowing them to return home after about 11 days, compared to 15 days for those who were treated with a placebo, according to the report in the New England Journal of Medicine.

Gilead’s remdesivir mainly helped healthier COVID-19 patients | coronavirus outbreak News,The Indian Express

A viral social media post falsely claims Dr. Anthony Fauci is "pushing" remdesivir as a potential COVID-19 treatment drug, because he "invented" it with Bill Gates and they stand to profit from it. Remdesivir was invented by the pharmaceutical company Gilead Sciences, which receives any profit from sales of the drug as a treatment for COVID-19.

Fauci Didn't Invent, Won't Profit from Remdesivir - FactCheck.org

FROM DR MARK CHEONG , School of Pharmacy Monash University MalaysiaFROM DR MARK CHEONG , School of Pharmacy Monash University Malaysia

Setting the price for a drug | The Star

“Maryland has now distributed 6,700+ vials of the antiviral drug remdesivir to hospitals statewide to help treat #COVID19 patients. I want to thank @HHSgov for their partnership as we direct this lifesaving treatment to the hardest-hit regions of our state.”

Governor Larry Hogan on Twitter: "Maryland has now distributed 6,700+ vials of the antiviral drug remdesivir to hospitals statewide to help treat #COVID19 patients. I want to thank @HHSgov for their partnership as we direct this lifesaving treatment to the hardest-hit regions of our state."

“Hetero Labs in Hyderabad seeks nod from govt to market remdesivir, a potential Covid drug @ChandnaHimani reports #ThePrintHealth https://t.co/4YoT9f8Ymy”

Shekhar Gupta on Twitter: "Hetero Labs in Hyderabad seeks nod from govt to market remdesivir, a potential Covid drug @ChandnaHimani reports #ThePrintHealth https://t.co/4YoT9f8Ymy"

“Indian pharmaceutical companies have taken a step forward towards bringing #remdesivir, a drug touted as a potential treatment for Covid-19, to India. ⁦@Cipla_Global⁩ and @HeteroLabs have sought a clinical trial waiver from the #DCGI https://t.co/zvflcxXmJ9”

Teena Thacker on Twitter: "Indian pharmaceutical companies have taken a step forward towards bringing #remdesivir, a drug touted as a potential treatment for Covid-19, to India. ⁦@Cipla_Global⁩ and @HeteroLabs have sought a clinical trial waiver from the #DCGI https://t.co/zvflcxXmJ9"

“Gilead Sciences statement on NEJM publication of Remdesivir data from NIAID study. (Remdesivir is an investigational antiviral drug that is being studied in multiple ongoing international clinical trials. Its safety & efficacy for treatment of #COVIDー19 are not yet established.)”

Siddharth Zarabi on Twitter: "Gilead Sciences statement on NEJM publication of Remdesivir data from NIAID study. (Remdesivir is an investigational antiviral drug that is being studied in multiple ongoing international clinical trials. Its safety & efficacy for treatment of #COVIDー19 are not yet established.)… https://t.co/eRqNsnetvz"

Rio Grande Valley hospitals will receive a drug used to treat the coronavirus, Texas Gov. Greg Abbott announced on Wednesday.Rio Grande Valley hospitals will receive a drug used to treat the coronavirus, Texas Gov. Greg Abbott announced on Wednesday.

Valley hospitals to receive antiviral drug used to treat coronavirus patients

Anti-viral remdesivir cuts COVID-19 recovery time, study saysAnti-viral drug remdesivir cuts recovery times in coronavirus patients, according to the full results of a trial published Friday night, three weeks after America's top...

Anti-viral remdesivir cuts COVID-19 recovery time, study says | Daily Sabah

Study suggests that remdesivir, when injected intravenously daily for 10 days accelerated the recovery of hospitalised COVID-19 patientsStudy suggests that remdesivir, when injected intravenously daily for 10 days accelerated the recovery of hospitalised COVID-19 patients

New study finds anti-viral drug remdesivir effective against coronavirus

Beximco was not issued a license by Gilead to sell a generic version of remdesivir, but can do so under provisions of a World Trade Organization agreement.Beximco was not issued a license by Gilead to sell a generic version of remdesivir, but can do so under provisions of a World Trade Organization agreement.

First generic remdesivir will be sold by Bangladesh drug maker

The country has gotten approval under World Trade Organization (WTO) provisions to produce generic versions of patented drugs.The country has gotten approval under World Trade Organization (WTO) provisions to produce generic versions of patented drugs.

Bangladesh Firm Becomes World's First Supplier Of Generic Drug Remdevisir For COVID-19 Treatment

The investigational antiviral remdesivir is superior to the standard of care for the treatment of COVID-19, according to a report published today in the New England Journal of Medicine. The preliminary analysis is based on data from the Adaptive COVID-19 Treatment Trial (ACTT), sponsored by the Nati

Remdesivir Improves Time to Recovery for COVID-19 in New England Journal of Medicine Study

Remdesivir Improves Time to Recovery for COVID-19 in New England Journal of Medicine Study – SciTechDaily

Contrarians are saying that while remdesivir can save lives, it will likely be nothing more than a one-time bonus to Gilead's bottom line. Here's why.Contrarians are saying that while remdesivir can save lives, it will likely be nothing more than a one-time bonus to Gilead's bottom line. Here's why.

Before You Buy Gilead Sciences Stock, Read This | The Motley Fool

Preliminary results from NIH clinical trial published.Preliminary results from NIH clinical trial published.

Peer-reviewed data shows remdesivir for COVID-19 improves time to recovery | National Institutes of Health (NIH)

Hetero Labs filed an application with the Central Drugs Standard Control Organisation (CDSCO) last week. The CDSCO may soon reach out to ICMR for suggestions.Hetero Labs filed an application with the Central Drugs Standard Control Organisation (CDSCO) last week. The CDSCO may soon reach out to ICMR for suggestions.

Hetero Labs in Hyderabad seeks nod from govt to market remdesivir, a potential Covid drug

Hetero Labs filed an application with the Central Drugs Standard Control Organisation (CDSCO) last week. The CDSCO may soon reach out to ICMR for suggestions.Hetero Labs filed an application with the Central Drugs Standard Control Organisation (CDSCO) last week. The CDSCO may soon reach out to ICMR for suggestions.

Hetero Labs in Hyderabad seeks nod from govt to market remdesivir, a potential Covid drug

The U.S. National Institutes of Health (NIH) on Friday said that data from its trial of Gilead Sciences Inc's remdesivir show that the drug offers the most benefit for COVID-19 patients who need extra oxygen but do not require mechanical ventilation.The U.S. National Institutes of Health (NIH) on Friday said that data from its trial of Gilead Sciences Inc's remdesivir show that the drug offers the most benefit for COVID-19 patients who need extra oxygen but do not require mechanical ventilation.

NIH trial: Gilead's drug works best in COVID patients on oxygen - Reuters

Patients taking remdesivir had a median recovery time of 11 days compared to 15 days for those taking a placeboPatients taking remdesivir had a median recovery time of 11 days compared to 15 days for those taking a placebo

Peer-Reviewed Data Shows Remdesivir Shortened Covid-19 Recovery Time

The peer-reviewed data was published in the New England Journal of Medicine. The trial, for which final results are still trickling in, showed that recovery time for patients given remdesivir was shortened by four days, or 31%, compared to placebo patients. The biggest benefit was seen in patientsThe peer-reviewed data was published in the New England Journal of Medicine. The trial, for which final results are still trickling in, showed that recovery time for patients given remdesivir was shortened by four days, or 31%, compared to placebo patients. The biggest benefit was seen in patients

NIH trial: Gilead's drug works best in COVID patients on oxygen

However, the result is just below the statistical reliability threshold, meaning it could be down to chance rather than the capability of the drugHowever, the result is just below the statistical reliability threshold, meaning it could be down to chance rather than the capability of the drug

US govt agency study finds anti-viral drug effective against coronavirus

Two thirds of patients UIHC has enrolled in its trial have recovered and been released.

Remdesivir: The Race for Relief and how UIHC is involved

U.S. doctors and others in the scientific community are calling for the release of data that convinced health regulators to authorize emergency use of Gilead Sciences Inc's antiviral drug remdesivir to treat COVID-19, so they can direct limited supplies on the right patients.U.S. doctors and others in the scientific community are calling for the release of data that convinced health regulators to authorize emergency use of Gilead Sciences Inc's antiviral drug remdesivir to treat COVID-19, so they can direct limited supplies on the right patients.

More than 130 drugs are under experimentation to treat Covid-19, some may have the potential to stop the virus while others may help calm overactive immune responses that damage organs, according to a tracker maintained by the Milken Institute, an independent economic think tank in the US.More than 130 drugs are under experimentation to treat Covid-19, some may have the potential to stop the virus while others may help calm overactive immune responses that damage organs, according to a tracker maintained by the Milken Institute, an independent economic think tank in the US.

Remdesivir tops list of Covid-19 drug contenders, say scientists - india news - Hindustan Times

Remdesivir has recently been authorised by the US for emergency use in the treatment of COVID-19 patients.Remdesivir has recently been authorised by the US for emergency use in the treatment of COVID-19 patients.

Bangladesh pharma giant introduces first generic version of remdesivir for COVID-19- The New Indian Express

BANGALORE (REUTERS) - The US National Institutes of Health (NIH) said on Friday (May 22) peer-reviewed data published in the New England Journal of Medicine show that Gilead Sciences' remdesivir is effective at helping Covid-19 patients recover.. Read more at straitstimes.com.United States News -BANGALORE (REUTERS) - The US National Institutes of Health (NIH) said on Friday (May 22) peer-reviewed data published in the New England Journal of Medicine show that Gilead

Peer-reviewed data shows Gilead's drug effective against Covid-19, United States News & Top Stories - The Straits Times

Gilead Sciences Inc.'s antiviral drug remdesivir improved COVID-19 patients' recovery time in peer-reviewed data from a study by the National Institute of...Gilead Sciences Inc.'s antiviral drug remdesivir improved COVID-19 patients' recovery time in peer-reviewed data from a study by the National Institute of...

Gilead's remdesivir improves time to recovery for COVID-19 patients in peer-reviewed results, NIAID says - MarketWatch

As COVID-19 continues its spread -- crossing 5.2 million cases and 3,38,000 fatalities on Saturday -- several categories of drugs are under clinical trial.As COVID-19 continues its spread -- crossing 5.2 million cases and 3,38,000 fatalities on Saturday -- several categories of drugs are under clinical trial.

Several drugs under trial for COVID-19, remdesivir leading contender: Scientists - Moneycontrol.com

Beximco Pharmaceuticals to give drug, which has been authorised by the US for emergency use in the treatment of coronavirus patients, for free to state-...Beximco Pharmaceuticals to give drug, which has been authorised by the US for emergency use in the treatment of coronavirus patients, for free to state-...

Bangladesh pharma giant to sell first generic version of remdesivir for Covid-19 - News | Khaleej Times

In hospitalized patients with severe COVID-19, the antiviral drug remdesivir reduced recovery time by about one-third, a large, multinational trial has found. Preliminary results were published today in the New England Journal of Medicine.In hospitalized patients with severe COVID-19, the antiviral drug remdesivir reduced recovery time by about one-third, a large, multinational trial has found. Preliminary results were published today

Remdesivir speeds recovery in cases of severe COVID-19 | Newsroom

The study, conducted on over 1,000 patients, also found that remdesivir is unlikely to be sufficient as a standalone treatment as it didn't significantly reduce the death rate.The study, conducted on over 1,000 patients, also found that remdesivir is unlikely to be sufficient as a standalone treatment as it didn't significantly reduce the death rate.

Remdesivir cuts recovery time of Covid patients from 15 days to 11: New peer-reviewed study

The study, conducted on over 1,000 patients, also found that remdesivir is unlikely to be sufficient as a standalone treatment as it didn't significantly reduce the death rate.The study, conducted on over 1,000 patients, also found that remdesivir is unlikely to be sufficient as a standalone treatment as it didn't significantly reduce the death rate.

Remdesivir cuts recovery time of Covid patients from 15 days to 11: New peer-reviewed study

Read more about First copies of Gilead coronavirus drug to start selling in Bangladesh on Business Standard. The Dhaka-based Beximco, which counts Norges Bank as one of its investors, will sell remdesivir for about 6,000 taka ($71) a vial to private clinics but will give it free to state-run hospitalsThe Dhaka-based Beximco, which counts Norges Bank as one of its investors, will sell remdesivir for about 6,000 taka ($71) a vial to private clinics but will give it free to state-run hospitals

First copies of Gilead coronavirus drug to start selling in Bangladesh | Business Standard News

Access Denied

Beximco Pharmaceuticals yesterday handed over the first batch of its antiviral drug remdesivir that has shown the most promise in treating Covid-19 patients by cutting the duration of symptoms from 15 days to 11. The delivery took place on the day the drug administration gave emergency authorisation to the company to market the drug with the brand name Bemsivir IV.Beximco Pharmaceuticals yesterday handed over the first batch of its antiviral drug remdesivir that has shown the most promise in treating Covid-19 patients by cutting the duration of symptoms from

Beximco hands over first batch of remdesivir to govt | The Daily Star

The medicine has been issued an Emergency Use Authorization (EUA) by the United States Food and Drug Administration (FDA) to treat hospitalised COVID-19 patients.  The medicine has been issued an Emergency Use Authorization (EUA) by the United States Food and Drug Administration (FDA) to treat hospitalised COVID-19 patients.  

US pharma firm Gilead Sciences likely to seek nod to market anti-viral drug remdesivir in India - World News

Bangladeshi firm debuts world’s first generic remdesivir for COVID-19 treatment

Bangladeshi firm debuts world’s first generic remdesivir for COVID-19

Anti-viral drug remdesivir cuts recovery times in coronavirus patients, according to the full results of a trial published Friday night, three weeks after America’s top infectious diseases expert said the study showed the medication has “clear-cut” benefits. Complete results from the research, which was carried out by US government agency the National Institute of Allergy […]

‘Clear-cut, significant and positive effect’: Anti-viral drug effective against coronavirus, study finds – Raw Story

Remdesivir could be the first real treatment for COVID-19 that finally gives humans even a slight upper hand against the microbe.Remdesivir was initally investigated as a treatment for another lethal viral disease, Ebola

How Remdesivir Moved From Back Shelf to Best Hope for COVID | Time

The Dhaka-based Beximco will sell Gilead's remdesivir for about 6,000 taka a vial to private clinics but will give it free to state-run hospitals treating Covid-19 patients.Bangladesh had more than 26,000 infected cases as of Wednesday, while the disease had killed 386The Dhaka-based Beximco will sell Gilead's remdesivir for about 6,000 taka a vial to private clinics but will give it free to state-run hospitals treating Covid-19 patients.Bangladesh had more than 26,000 infected cases as of Wednesday, while the disease had killed 386

Bangladesh company is the first to sell copies of Gilead's coronavirus drug

Just a moment...

Beximco Pharmaceuticals has launched the first generic version of antiviral drug remdesivir, which was originally developed by Gilead Sciences.

Beximco Pharmaceuticals launches first generic remdesivir for Covid-19

Preliminary information showed remdesivir has promising results in shortening the duration of COVID-19 by about a third. But there are still questions about the drug's risks and side effects.Preliminary information showed remdesivir has promising results in shortening the duration of COVID-19 by about a third. But there are still questions about the drug's risks and side effects.

Remdesivir Arrives In D.C. Region, Bringing Possible Help In Treating COVID-19 | DCist

All the news from Bangladesh regarding politics, business, industry, lifestyle, culture, sports, crime. The sharpest opinions and op-eds from the country.

Page not found | Dhaka Tribune

The Financial Express (FE) is the first financial daily of Bangladesh in English under the ownership of company -- International Publications Limited which was incorporated under the Companies Act in the year, 1993. The FE started its journey in 1993. In terms of circulation this daily now ranks second, both in its print and on online editions, among its contemporaries, in English language, in Bangladesh. It has currently syndication arrangements with the London-based Financial Times (FT) and the Prague-based Project Syndicate. Beximco Pharmaceuticals on Thursday announced the launch of Remdesivir, an antiviral drug which has recently been given US FDA “Emergency Use Authorisation” for treatment of COVID-19 patients.   With the launch of Remdesivir – which is being branded under the name of Bemsivir – Beximco Pharmaceuticals becomes the first company in the world to have launched a generic version of this highly anticipated drug. It is also the first drug to be found effective in stopping the replication of SARS-CoV-2.   The launching of the antiviral drug was announced during a simple ceremony at the Health Ministry on the day in presence of Mr Zahid Maleque MP, Minister for Health and Family Welfare, Government of the People’s Republic of Bangladesh.   Mr. Md. Asadul Islam, Secretary, Health Care Division, Mr. Md. Ali Noor, Secretary, Health Education and Family Welfare Division, Major General Md. Mahbubur Rahman, Director General, Directorate General of Drug Adminstration (DGDA), Prof Dr. A B M Abdullah, Personal Physician to Prime Minister, and Brigadier General Md. Shahidullah, Director, Central Medical Stores Depot, were also present on this occasion.   While handing over the first batch of medicine, Managing Director of Beximco Pharma Nazmul Hassan MP said all government hospital treat patients free of cost. “And therefore, we have decided to provide Bemsivir free of cost to all those severely ill patients of government hospitals.”   Beximco Pharma, listed on the Alternate investment Market (AIM) of London Stock Exchange, was the first company in Bangladesh to apply for regulatory approval, duly completing all the processes, strictly in compliance with local regulations. Following thorough evaluation, Directorate General of Drug Administration (DGDA) granted Emergency Use Authorization to Beximco Pharma’s Remdesivir IV Injection (under the brand name Bemsivir) on 21 May 2020.   Originally developed by US based Gilead Sciences, Remdesivir is a direct acting antiviral drug that inhibits viral RNA synthesis. Remdesivir is administered intravenously and is authorized for the treatment of hospitalized patients with severe COVID-19 disease.   Recent clinical trials have shown evidence that Remdesivir helps severe COVID-19 patients recover faster. Japan Government has also granted Special Approval for Remdesivir in emergency treatment of COVID-19.   The emergency approvals will help broaden use of Remdesivir in hospitalized patients, especially in developing and least developed countries where access to breakthrough, advanced drugs remains a major challenge, said Nazmul Hassan MP, Managing Director of Beximco Pharma.   “We are pleased to be the first generic company in the world to introduce this very important drug for treating the hospitalized COVID-19 patients. This reinforces our commitment to play our part in ensuring access to breakthrough therapies despite facing many challenges amid this unprecedented pandemic. We express our gratitude to the regulatory authorities for extending their wholehearted support for making this potential drug available to our patients at the earliest possible time. As a responsible Company, we will continue to extend our support to the Government in all possible ways during this national emergency,” said Nazmul Hassan MP, Managing Director of Beximco Pharma.    He said Beximco Pharma will supply Remdesivir (Bemsivir) to Government designated hospitals for COVID-19 treatment, and not to be available through retail pharmacies, in compliance with the directives from Bangladesh drug regulatory authorities. On the very first day of receiving regulatory approval, Beximco Pharma has donated large quantities of Remdesivir (Bemsivir) to Bangladesh Government for the treatment of COVID-19 patients.   Mr Zahid Maleque MP, Minister for Health and Family Welfare, Government of the People’s Republic of Bangladesh, lauded Beximco Pharma for its initiatives during this time of pandemic.   Mr. Nazmul Hassan MP, Managing Director of Beximco Pharmaceuticals, commented: In response to the coronavirus pandemic, Beximco Pharma has taken various proactive measures to provide the latest, evidence-based treatment options for the COVID-19 patients. The Company is committed to fighting this unprecedented pandemic, in all possible ways, employing its competitive R&D and manufacturing skills. Beximco Pharma has already launched another anti-viral drug Favipiravir (under the brand name Viraflu), as well as repurposed antimalarial drug hydroxychlorquine (under the brand name Kovicin) and anti-parasitic drug Ivermectin (under the brand name Ivera) as potential COVID-19 treatment.  -rmc//

Beximco Pharma introduces world’s first generic Remdesivir for COVID-19 treatment